Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

Alexander P. Davis; Wendy A. Cooper; Michael Boyer; Jenny H. Lee; Nick Pavlakis; Steven C. Kao

doi:10.2217/imt-2021-0090

Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

Alexander P. Davis, Wendy A. Cooper, Michael Boyer, Jenny H. Lee, Nick Pavlakis, Steven C. Kao

Western Sydney University

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the US FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.

Original language	English
Pages (from-to)	941-952
Number of pages	12
Journal	Immunotherapy
Volume	13
Issue number	11
DOIs	https://doi.org/10.2217/imt-2021-0090
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2021-0090

Cite this

@article{49372e3b42c94923ab0a77082a9e0d2b,

title = "Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations",

abstract = "KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the US FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.",

author = "Davis, {Alexander P.} and Cooper, {Wendy A.} and Michael Boyer and Lee, {Jenny H.} and Nick Pavlakis and Kao, {Steven C.}",

year = "2021",

doi = "10.2217/imt-2021-0090",

language = "English",

volume = "13",

pages = "941--952",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor & Francis",

number = "11",

}

TY - JOUR

T1 - Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

AU - Davis, Alexander P.

AU - Cooper, Wendy A.

AU - Boyer, Michael

AU - Lee, Jenny H.

AU - Pavlakis, Nick

AU - Kao, Steven C.

PY - 2021

Y1 - 2021

N2 - KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the US FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.

AB - KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung adenocarcinoma in western populations. No KRAS specific therapy has been approved by the US FDA until 2021. Despite significant heterogeneity in comutations, patients typically receive single-agent immunotherapy or chemoimmunotherapy as standard first-line therapy. It is unclear whether KRAS mutations predict outcomes with immunotherapy; however, there is emerging data suggesting improved outcomes in patients with a TP53 comutation and worse outcomes in patients with a STK11/LKB1 or KEAP1 comutation.

UR - https://hdl.handle.net/1959.7/uws:65873

U2 - 10.2217/imt-2021-0090

DO - 10.2217/imt-2021-0090

M3 - Article

SN - 1750-743X

VL - 13

SP - 941

EP - 952

JO - Immunotherapy

JF - Immunotherapy

IS - 11

ER -

Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this